Longevity Health Stock Soars 101.13% on True Health Merger

On July 15, 2025, Longevity Health's stock surged by 101.13% in pre-market trading, marking a significant milestone for the company.

Longevity Health Holdings, Inc. has entered into a definitive merger agreement with True Health Inc., a leading player in the plasma collection industry. This all-stock transaction is expected to combine the strengths of both companies, with the merged entity continuing to trade on Nasdaq under the symbol "XAGE." The merger follows Longevity's previous acquisitions of Carmell Therapeutics and Elevai Skincare, both of which focus on plasma-derived growth factors and exosomes derived from human stem cells, respectively.

True Health Inc., operating under the THPlasma brand, has shown rapid growth with a footprint of plasma collection centers in the Northeast United States. The company has long-term partnerships for guaranteed sales offtake agreements, achieving cash profitability in FY2024. The merger is expected to drive further growth through acquisitions and organic expansion, with THPlasma valued at $59 million plus a $20 million earnout linked to financial performance.

The merger has been unanimously approved by the boards of both companies and is expected to close in the fourth quarter of 2025, subject to customary closing conditions and stockholder approvals. The transaction is seen as a transformative step for both companies, unlocking access to public markets and future M&A opportunities, and is expected to supercharge growth and deliver value across the board.